Capstan Therapeutics is advancing precision in vivo cell engineering to develop therapeutics for a broad range of disease categories with unmet or underserved clinical need.
Dren Bio is a biotechnology company with a portfolio of attractive projects focused on powerful protein engineering technologies for the depletion of cells, protein aggregates, and other disease-causing agents. It is a holding company business model aimed at creating value with multiple projects as stand-alone assets.
Developer of a multi-omic instrument designed for biological target detection for clinical testing and biomedical research. The company's platform provides monitoring of minimal residual disease and early multi-cancer screening, also detects a diverse collection of analytical targets that includes DNA, RNA, and protein biomarkers with unprecedented speed and precision, and leverages advanced microfluidics to automate all aspects of sample preparation and analysis, enabling healthcare providers to get access to diverse health monitoring technologies.
Eclipse Bioinnovations, founded in 2017, specializes in RNA Next-Generation Sequencing (NGS) technologies developed from research in Professor Gene Yeo's laboratory at UC San Diego. The company focuses on advancing RNA medicines through its Eclipse-Seq platform, which aims to enhance the safety and efficacy of these treatments. One of its key innovations is eCLIP, a unique and efficient technology for identifying RNA binding protein partners and mapping genes. Eclipse offers eCLIP both as a service and a kit, catering to biopharma companies and academic researchers. The technology is adaptable for various RNA types, including siRNA and miRNA, assisting scientists in identifying RNA binding protein targets, thereby facilitating research and the development of new drugs to address a wide range of diseases.
NextVivo is a biotech company developing an immune organoid technology platform to transform the future of drug development. Its mission is to accelerate the development of safer, more effective therapies that are generated and tested in immune-competent human-derived models.
Parthenon Therapeutics is inventing a novel class of anti-cancer therapies that reprogram the tumor microenvironment (TME). The interplay between cancer cells and their surrounding microenvironment is relevant in drug development as manycancers use the TME to build barriers that shield immune system attack. One approach, PRTH-101, breaks these barriers to overcome recalcitrant cancers. Based on research, the company is designing a portfolio of drug candidates to treat the right patients at the right time.
Nitrase Therapeutics is a biopharmaceutical company focused on discovering and developing drugs targeting a newly identified class of enzymes known as Nitrases. Initially concentrating on Parkinson’s disease, Nitrase aims to create therapies that may slow or halt the progression of this neurodegenerative condition. Beyond its primary focus, the company plans to expand its research to address other aging-related diseases, including Type II diabetes, heart disease, and various cancer types. Founded in 2012 and headquartered in Jackson, Wyoming, with additional facilities in San Francisco, California, Nitrase Therapeutics is positioned to contribute significantly to the treatment of complex diseases associated with aging.
Immunai Inc. is a biotechnology company focused on developing an artificial intelligence-based immune profiling platform aimed at enhancing drug development, disease detection, diagnosis, and treatment. The company utilizes single-cell genomics and machine learning to conduct high-resolution profiling of the immune system at an industrial scale, generating valuable biological insights that facilitate research and promote novel discoveries. Immunai's platform supports biomarker discovery and helps understand how various cell types respond to their changing environments. Its research and development efforts concentrate on cancer therapies, including blockade and vaccine strategies. The company collaborates with academic institutions, biopharmaceutical firms, and other biotechnology companies to advance its mission of mapping the immune system. Founded in 2018, Immunai is headquartered in New York City, with additional offices in San Francisco, California, and Tel Aviv, Israel.
Cyrus Biotechnology builds software tools to accelerate basic research in biotech, pharma, and industrial biotechnology. Cyrus Bench delivers an enterprise version of the Rosetta molecular modeling and design toolkit, with the associated array of bio-molecular computation tools.
It was founded in 2014 and headquartered in Seattle, Washington.
Neurona Therapeutics Inc. develops cell-based therapies for the treatment of neurological disorders. The company develop therapeutic compositions of specific nerve cells for targeted delivery into the injured nervous system. The company was incorporated in 2008 and is based in South San Francisco, California.
Molecular Assemblies, Inc. is a San Diego-based company that specializes in enzymatic DNA synthesis technology, which allows for the precise reading and writing of DNA. Founded in 2013, the company targets multiple markets, including life sciences, industrial applications, information storage, nanotechnology, and DNA electronics. Its innovative approach is inspired by natural processes and focuses on producing long, high-quality, sequence-specific DNA in a reliable, affordable, and sustainable manner. The company boasts a strong executive and scientific team and holds an extensive intellectual property portfolio. It has garnered investments from various notable entities, highlighting its potential to advance products in industrial synthetic biology, personalized therapeutics, and precision diagnostics.
Blacksmith Medicines developing medicines targeting metal-dependent enzymes found in human physiology. Over 30% of known enzymes are metalloenzymes, covering all major enzyme classes: oxidoreductases, transferases, hydrolases, lyases, isomerases, and ligases. Metal ions, including magnesium, zinc, iron, manganese and copper, are the essential ingredient in these metalloenzymes.
Dren Bio is a biotechnology company with a portfolio of attractive projects focused on powerful protein engineering technologies for the depletion of cells, protein aggregates, and other disease-causing agents. It is a holding company business model aimed at creating value with multiple projects as stand-alone assets.
Nitrase Therapeutics is a biopharmaceutical company focused on discovering and developing drugs targeting a newly identified class of enzymes known as Nitrases. Initially concentrating on Parkinson’s disease, Nitrase aims to create therapies that may slow or halt the progression of this neurodegenerative condition. Beyond its primary focus, the company plans to expand its research to address other aging-related diseases, including Type II diabetes, heart disease, and various cancer types. Founded in 2012 and headquartered in Jackson, Wyoming, with additional facilities in San Francisco, California, Nitrase Therapeutics is positioned to contribute significantly to the treatment of complex diseases associated with aging.
Novome Biotechnologies, Inc. is a biotechnology company based in South San Francisco, California, that specializes in engineering bacteria from the human gut to address chronic diseases. Founded in 2015, the company has developed a platform for the controlled colonization of the gut with genetically engineered bacteria, known as Genetically Engineered Microbial Medicines (GEMMs). This innovative approach allows for sustained therapeutic interventions through the precise delivery of microbial activities. Novome's lead preclinical program targets hyperoxaluria by creating a therapeutic strain of bacteria aimed at degrading oxalate to help prevent kidney stone formation. The company is also expanding its synthetic biology platform to explore additional therapeutic applications.
Aspen Neuroscience, Inc. is a biotechnology company based in San Diego, California, focused on developing induced pluripotent stem cell therapies for neurological conditions, particularly Parkinson's disease. Founded in 2018, the company aims to create patient-specific restorative cell therapies that can alter the progression of the disease. Its product pipeline includes ANPD001, an autologous neuron replacement therapy designed for sporadic Parkinson's disease, and ANPD002, a gene-edited version targeting familial forms of the disease. By integrating innovative genomic approaches with stem cell biology, Aspen Neuroscience seeks to advance the field of personalized medicine and improve treatment outcomes for patients suffering from Parkinson's disease.
Molecular Assemblies, Inc. is a San Diego-based company that specializes in enzymatic DNA synthesis technology, which allows for the precise reading and writing of DNA. Founded in 2013, the company targets multiple markets, including life sciences, industrial applications, information storage, nanotechnology, and DNA electronics. Its innovative approach is inspired by natural processes and focuses on producing long, high-quality, sequence-specific DNA in a reliable, affordable, and sustainable manner. The company boasts a strong executive and scientific team and holds an extensive intellectual property portfolio. It has garnered investments from various notable entities, highlighting its potential to advance products in industrial synthetic biology, personalized therapeutics, and precision diagnostics.
Cardea Bio, Inc. is a biotechnology company based in San Diego, California, specializing in bioelectronics and graphene-based digital biosensor technology. Founded in 2013, the company develops products that facilitate precision healthcare by enhancing the ease, speed, and cost-effectiveness of diagnostics. Its key offerings include AGILE R100, an innovative assay for small molecule drug discovery, and AGILE R200, an automated high-throughput screening solution. Cardea's biosensors utilize biocompatible graphene to transform biological signals into digital data, enabling real-time analysis of biomolecules. This technology supports applications in small molecule validation, antibody characterization, and biomolecular analysis, serving the life sciences and healthcare sectors. The company also sells its products online, contributing to advancements in research and diagnostics.
Ribometrix, Inc. is a biotechnology company based in Durham, North Carolina, founded in 2014. The company focuses on discovering and developing small molecule drugs that specifically target functional three-dimensional RNA structures to treat various human diseases. Ribometrix employs advanced techniques in RNA structural analysis, utilizing proprietary methods and state-of-the-art tools to identify novel small molecules that can inhibit the production of disease-associated proteins. By integrating artificial intelligence and machine learning capabilities, the company aims to enhance its understanding of RNA biology and its implications in health and disease. Ribometrix operates scientific offices in a renovated space in Durham, with additional locations in Chapel Hill and Boston.
Inspirna is a biopharmaceutical company focused on discovering and developing innovative therapeutic targets and drugs for various cancer subtypes, including melanoma, colorectal cancer, and triple-negative breast cancer. Utilizing a proprietary microRNA-based target discovery platform, Inspirna identifies and validates novel post-transcriptionally regulated targets, leading to the creation of first-in-class therapeutics. The company has developed several promising drug candidates, such as RGX-104, an oral small molecule designed for treating solid tumors, RGX-202, which targets cancer metabolism in gastrointestinal cancers, and RGX-019, a monoclonal antibody aimed at disrupting pathways that promote tumor progression and metastasis. Founded in 2010 and headquartered in New York, Inspirna strives to transform the lives of cancer patients by providing safe and effective therapies for metastatic disease.
MouSensor, Inc. is a biotechnology company founded in 2016 and based in New York, New York. The company specializes in developing a platform to digitize the sense of smell by engineering super sniffer mice. This innovation allows for the creation of a live nose-on-a-chip capable of detecting and digitizing a wide range of odors, including fragrances used in perfumery and specific scents linked to diseases such as Parkinson's disease. As an early-stage biotech firm, MouSensor aims to advance the understanding and application of olfactory technology in various fields.
ENB Therapeutics, LLC develops small molecule inhibitors to treat melanoma and other cancers. The product includes ENB-001 that restores the ability of T-cells to infiltrate tumors and inhibits metastasis. The company was incorporated in 2015 and is based in New York, New York.
Biodesy has developed a unique and highly sensitive means of detecting conformational change in proteins and other biological molecules. Our technology, based on a phenomenon called ‘second-harmonic generation’ (SHG), can monitor structural change at any site within a protein, in real time.
Magnolia Neurosciences Corporation is a New York-based company focused on drug discovery and development, specifically targeting neuroprotective therapies for central nervous system diseases and neurodegeneration. Established in 2018, the company aims to create proprietary small molecule therapeutics that prevent neuronal cell death, offering new treatment options for patients with neurodegenerative disorders and related conditions. Magnolia Neurosciences was founded to advance technologies developed at The University of Texas MD Anderson Cancer Center’s Therapeutics Discovery Division and the Neurodegeneration Consortium. Through its innovative approach, the company seeks to address significant medical needs in the field of neurology.
Nohla Therapeutics' singular passion is the development of best-in-class ex vivo expanded universal donor cellular therapies to transform the treatment of patients with cancer and other life threatening illnesses. Our products are manufactured and cryopreserved on an ongoing basis allowing for a bank of doses that are available for immediate (on demand) use. This is tremendously advantageous with regards to the ease and timing of treatment, the ability to provide repeated dosing for immune-oncology indications and reduction in patient risk and cost relative to other cell therapies.
Nohla Therapeutics' singular passion is the development of best-in-class ex vivo expanded universal donor cellular therapies to transform the treatment of patients with cancer and other life threatening illnesses. Our products are manufactured and cryopreserved on an ongoing basis allowing for a bank of doses that are available for immediate (on demand) use. This is tremendously advantageous with regards to the ease and timing of treatment, the ability to provide repeated dosing for immune-oncology indications and reduction in patient risk and cost relative to other cell therapies.
Expansion Therapeutics is a drug discovery and development company pursuing the vast potential of small molecule medicines for RNA-mediated diseases.
Aura Biosciences, Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, focused on developing therapies to target and destroy cancer cells using viral nanoparticle conjugates. The company’s lead product, AU-011, utilizes viral nanoparticles modeled on the human papillomavirus, conjugated with infrared-activated small molecules, specifically for the treatment of ocular melanoma, a primary eye cancer. By employing nanotechnology, Aura aims to safely eliminate cancer locally, particularly in early-stage cases, to prevent progression to more severe forms of the disease, such as metastasis to the liver. Additionally, the company is advancing its bel-sar candidate for treating primary choroidal melanoma and exploring applications in bladder cancer. Founded in 2007, Aura Biosciences is committed to developing precision immunotherapies that preserve the function of organs affected by cancer.
Obsidian Therapeutics develops innovative cell and gene therapies aimed at enhancing adoptive immunotherapy for cancer patients. Founded in 2015 and based in Cambridge, Massachusetts, the company focuses on creating next-generation therapies that utilize pharmacologic operating systems to provide precise control over protein activity within cells. This technology allows for the development of adoptive cell therapies with advanced functionalities that can be managed by physicians using simple, safe, and orally active medications. By offering improved control over treatment, Obsidian Therapeutics aims to provide better outcomes for patients compared to existing cell therapy options.
Ribometrix, Inc. is a biotechnology company based in Durham, North Carolina, founded in 2014. The company focuses on discovering and developing small molecule drugs that specifically target functional three-dimensional RNA structures to treat various human diseases. Ribometrix employs advanced techniques in RNA structural analysis, utilizing proprietary methods and state-of-the-art tools to identify novel small molecules that can inhibit the production of disease-associated proteins. By integrating artificial intelligence and machine learning capabilities, the company aims to enhance its understanding of RNA biology and its implications in health and disease. Ribometrix operates scientific offices in a renovated space in Durham, with additional locations in Chapel Hill and Boston.
Cydan Development, Inc. is a company focused on the development and commercialization of therapies for orphan and rare diseases, with a particular emphasis on rare genetic disorders. Founded in 2012 and located in Lincoln, Massachusetts, Cydan functions as an orphan drug accelerator, identifying and de-risking compounds with therapeutic potential. The organization conducts comprehensive studies to support the further development of treatments by biotechnology firms. Cydan has worked on therapies for conditions such as Niemann-Pick Disease Type C and IMR-687 for sickle cell disease. The company leverages strong relationships with academic institutions and patient advocacy groups, along with deep expertise in drug development, to foster successful product commercialization and advance treatment options for underserved patient populations.
Forge Therapeutics, Inc is a biotechnology company discovering and developing novel therapeutics using an innovative chemistry platform targeting metalloproteins. Forge uses a proprietary approach combining bioinorganic (study of metals in biology) and medicinal chemistry to generate selective inhibitors of this large class of targets.
Boragen Inc. is a biotechnology company based in Durham, North Carolina, that specializes in designing and developing multifunctional small molecule boron solutions for applications in crop protection, animal health, and human health. Founded in 2015, the company focuses on creating next-generation fungicides through its synthetic chemistry platforms, which aim to promote sustainable farming practices. Boragen's product pipeline includes BAG8, a boron-based multisite fungicide, and BN2266, which targets mRNA processing as a crop protection fungicide. Additionally, the company is developing a dual-function nematicide-fungicide designed for root protection and endo-parasiticides that address resistance challenges. Through its innovative approach, Boragen seeks to enhance agricultural efficiency while minimizing chemical usage.
Kinestral Technologies, Inc. specializes in manufacturing smart-tinting glass, branded as Halio, for both commercial and residential applications. Halio glass can transition from clear to tinted or dark, either automatically or on command, enhancing architectural design by providing versatile solutions for windows, walls, and skylights. This technology offers significant advantages over traditional electrochromic glass, including faster tinting, uniform coloration, and a natural appearance. Kinestral also provides a range of supporting products, such as the Halio Tint Selector, which allows localized control of window tinting, and Halio Cloud, an interface for integrating window operations with building automation systems. Founded in 2010 and headquartered in Hayward, California, Kinestral has established a strategic partnership with Asahi Glass Co., Ltd. Its advanced manufacturing techniques ensure reliable production and timely delivery for projects worldwide, ultimately aiming to improve energy efficiency and comfort in indoor environments.
ApoGen Biotechnologies, Inc. is focused on the development of new class of therapeutics targeting drivers of cancer genomic mutation.As the arsenal of available cancer therapies has grown and evolved from cytotoxic chemotherapy to targeted therapy to immunotherapy, one fact has unfortunately remained constant nearly all cancer drug therapies eventually fail due to the development of drug resistance. Mutation of cellular DNA is central to the formation of cancer, and chronic mutation of the cancer genome is a primary cause of cancer evolution and drug resistance, resulting in ineffective therapy, cancer recurrence and metastasis, and decreased overall survival.
Molecular Assemblies, Inc. is a San Diego-based company that specializes in enzymatic DNA synthesis technology, which allows for the precise reading and writing of DNA. Founded in 2013, the company targets multiple markets, including life sciences, industrial applications, information storage, nanotechnology, and DNA electronics. Its innovative approach is inspired by natural processes and focuses on producing long, high-quality, sequence-specific DNA in a reliable, affordable, and sustainable manner. The company boasts a strong executive and scientific team and holds an extensive intellectual property portfolio. It has garnered investments from various notable entities, highlighting its potential to advance products in industrial synthetic biology, personalized therapeutics, and precision diagnostics.
Yumanity Therapeutics is a biotechnology company dedicated to transforming drug discovery for neurodegenerative diseases linked to protein misfolding. Founded in December 2014 by protein folding expert Susan Lindquist and biotech leader Tony Coles, Yumanity aims to develop innovative, disease-modifying therapies to address critical unmet medical needs in conditions such as Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis (ALS). The company leverages proprietary platforms to identify potential therapeutic targets and has made progress in advancing a new chemical lead series specifically for Parkinson’s disease, while also exploring additional compounds for Alzheimer's disease and ALS.
NextCure, Inc. is a clinical-stage biopharmaceutical company based in Beltsville, Maryland, dedicated to discovering and developing innovative immunomedicines for cancer and other immune-related diseases. The company’s lead product candidate, NC318, is currently undergoing Phase 2 clinical trials aimed at treating advanced or metastatic solid tumors. Additionally, NextCure is advancing NC410, an immunomedicine designed to counteract immune suppression through targeting an immune modulator known as Leukocyte-Associated Immunoglobulin-like Receptor 1. The company is also engaged in research programs evaluating novel immunomodulatory molecules, including antibodies in preclinical development that target specific immune modulators in inflamed tissues and tumor microenvironments. NextCure has established a license agreement with Yale University and collaborates with Eli Lilly and Company for research and development efforts. Founded in 2015, the company leverages proprietary platforms to identify biologically relevant targets and develop first-in-class immunotherapy products.
Aura Biosciences, Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, focused on developing therapies to target and destroy cancer cells using viral nanoparticle conjugates. The company’s lead product, AU-011, utilizes viral nanoparticles modeled on the human papillomavirus, conjugated with infrared-activated small molecules, specifically for the treatment of ocular melanoma, a primary eye cancer. By employing nanotechnology, Aura aims to safely eliminate cancer locally, particularly in early-stage cases, to prevent progression to more severe forms of the disease, such as metastasis to the liver. Additionally, the company is advancing its bel-sar candidate for treating primary choroidal melanoma and exploring applications in bladder cancer. Founded in 2007, Aura Biosciences is committed to developing precision immunotherapies that preserve the function of organs affected by cancer.
Cydan Development, Inc. is a company focused on the development and commercialization of therapies for orphan and rare diseases, with a particular emphasis on rare genetic disorders. Founded in 2012 and located in Lincoln, Massachusetts, Cydan functions as an orphan drug accelerator, identifying and de-risking compounds with therapeutic potential. The organization conducts comprehensive studies to support the further development of treatments by biotechnology firms. Cydan has worked on therapies for conditions such as Niemann-Pick Disease Type C and IMR-687 for sickle cell disease. The company leverages strong relationships with academic institutions and patient advocacy groups, along with deep expertise in drug development, to foster successful product commercialization and advance treatment options for underserved patient populations.